Table 7: Predictive value of Oncoytpe-DX for overall survival in women with lymph-node-positive disease in a trial by Albain (38).
| Arm | Sample Size (Events) |
Cox Proportional HR for Death Due to Any Cause for Chemotherapy vs. Tamoxifen by Oncotype-DX Risk Group (95% CI) |
Cox Proportional HR For Continuous RS* |
|---|---|---|---|
| Tamoxifen | 148 (43) |
High 0.56 (0.31–1.02) P-value 0.057 Intermediate 0.84 (0.40–1.78) P-value 0.65 |
All years HR NR P-value 0.026 First 5 years HR NR P-value 0.016 |
| CAF→T | 219 (51) |
Low 1.18 (0.55–2.54) P-value 0.68 |
After 5 years HR NR P-value 0.87 |
*
Tests the interaction between 50-point increment in continuous recurrence score and chemotherapy benefit
Abbreviations: CI, confidence interval; CAF, cyclophosphamide, doxorubicin, fluorouracil 5-FU; HR, hazard ratio; RS, recurrence score.